Breaking

Israel confirms it is arming Hamas rivals in operation opposition calls ‘complete madness’
US Capital Global Facilitates $50MM Financing to Accelerate Charbone Hydrogen’s North American Expansion
China-appointed Panchen Lama vows to make religion more Chinese in meeting with Xi Jinping
Trump-Xi call restores trade truce. But the supply chain war has no end in sight
Justin Huhn: Uranium Game On — Supply “Mirage,” De-risked Demand, Next Price Move
North Korea refloats destroyer that capsized during launch, surprising naval analysts
Shein and Temu see U.S. demand plunge as loophole for cheap goods closes
Offer Booklet – Non-Renounceable Entitlement Offer

Facebook
Twitter
Google Plus
Instagram
Pinterest
Vimeo

Investing
Stock
Latest News
Editor’s Pick
Economy
Search for:

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

By June 4, 2025

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

US Capital Global Facilitates $50MM Financing to Accelerate Charbone Hydrogen’s North American Expansion

Justin Huhn: Uranium Game On — Supply “Mirage,” De-risked Demand, Next Price Move

Offer Booklet – Non-Renounceable Entitlement Offer

Enter Your Information Below To Receive Latest News, And Articles.
Your name

Your email
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest Posts
Categories
- Economy (865)
- Editor's Pick (449)
- Investing (3,274)
- Latest News (3,330)
- Stock (1,161)
About Rightinvestingway

Disclaimer: Rightinvestingway.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 Rightinvestingway.com

Top

Type above and press Enter to search. Press Esc to cancel.